Oxford-Based Precision Health Firm Appoints New CEO
1 report, 1 independent
Updated Tue 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Perspectum, a precision health company based in Oxford, England, announced the appointment of Warren Cresswell as Chief Executive Officer. Cresswell brings over 25 years of experience across diagnostics, pharmaceuticals, and medical devices, including building infrastructure for FDA-cleared diagnostics in the United States.
From prnewswire.com
Why it matters
Perspectum delivers non-invasive solutions aimed at improving patient outcomes in liver and cardiometabolic disease. The CEO's background in scaling organizations and managing FDA-cleared diagnostics could support the company's expansion and advancement of its innovative technologies.
From prnewswire.com
Who's involved
Keep exploring
The entities involved
- FDA
-
Oxford
city in Oxfordshire, England
- Scholars from the University of Toronto conducted research on the Arctic and compared its standing to institutions like Harvard and Oxford.
- OXB, a company, has established operational bases across Europe, including headquarters in Oxford, development facilities in Lyon, and manufacturing sites in Strasbourg.
Related events
- Williams led development to achieve FDA clearance.
- FDA clearance drives market expansion and coverage for NeurAxis, Inc.
- Future sales of a product are contingent upon obtaining the necessary FDA registration and labeling, while the state simultaneously announces actions to remove regulatory barriers.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- FDA approval enables commercial availability for a product associated with Indianapolis.